乐普医疗(300003) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥1,401,585,073.03, a decrease of 28.41% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥105,413,614.27, down 73.12% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥86,927,048.85, a decline of 77.19% compared to the previous year[3]. - Cumulative revenue for the year-to-date was ¥4,785,471,627.57, representing a decrease of 23.55% year-on-year[3]. - Total operating revenue for Q3 2024 was CNY 4,785,471,627.57, a decrease of 23.6% compared to CNY 6,259,227,849.28 in the same period last year[22]. - The net profit for Q3 2024 was approximately ¥783.35 million, a decrease of 44.1% compared to ¥1.40 billion in Q3 2023[23]. - The company reported a total comprehensive income of ¥773.44 million, compared to ¥1.47 billion in the previous year, reflecting a decrease of 47.4%[23]. - The basic earnings per share for Q3 2024 was ¥0.4339, down from ¥0.7268 in Q3 2023, representing a decline of 40.3%[23]. Cash Flow and Financing - The company reported a net cash flow from operating activities of ¥423,055,774.84, down 29.93% year-on-year[3]. - Cash flow from operating activities generated a net amount of ¥423.06 million, a decline of 30% from ¥603.78 million in Q3 2023[24]. - The company raised approximately ¥3.10 billion through borrowings in Q3 2024, an increase of 21.9% compared to ¥2.54 billion in Q3 2023[25]. - The total cash outflow from financing activities was ¥3.49 billion, up from ¥3.05 billion in the same period last year[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥25,006,284,390.10, a slight decrease of 0.06% from the end of the previous year[3]. - Total assets as of Q3 2024 were CNY 25,006,284,390.10, slightly down from CNY 25,022,331,486.69 at the end of the previous period[21]. - Total liabilities increased to CNY 7,704,983,084.66 from CNY 7,524,776,366.09, indicating a rise of approximately 2.4%[21]. - Current liabilities decreased significantly to CNY 2,627,681,823.66 from CNY 3,758,655,939.45, a reduction of about 30.1%[21]. - Long-term borrowings rose to CNY 2,860,653,053.85 from CNY 1,542,190,754.84, an increase of 85.6%[21]. Research and Development - The company experienced a significant increase in R&D expenses due to the progress of its cardiovascular innovative drug company, Shanghai Minwei Biotechnology[7]. - Research and development expenses for Q3 2024 amounted to CNY 557,054,487.38, a decrease of 17.5% compared to CNY 674,829,181.31 in the previous year[22]. Inventory and Assets Management - The company's inventory stock increased to 608.49 million yuan, an increase of 177.43 million yuan from the beginning of the year, a growth of 41.16% due to stock repurchase[11]. - The total inventory decreased from RMB 2,289,473,586.38 to RMB 2,216,459,996.88, a decrease of approximately 3.18%[19]. - The company's fixed assets at the end of the reporting period were 4.05 billion yuan, an increase of 1.24 billion yuan from the beginning of the year, a growth of 43.96%[9]. Non-Operating Income and Expenses - The company's non-operating income decreased to 12.08 million yuan, down 35.97 million yuan from the previous year, a reduction of 74.86%[9]. - The company's non-operating expenses increased to 19.91 million yuan, up 13.27 million yuan year-on-year, an increase of 199.93%[9]. Investment and Fair Value Changes - The company reported an investment loss of ¥1,171.40 million, a decrease of 71.38% compared to the previous year[7]. - The fair value change loss was ¥1,119.96 million, an increase of 378.78% year-on-year, primarily due to currency fluctuations affecting foreign currency financial products[8]. Shareholder Information - The total cash dividend distributed to shareholders amounted to RMB 261,762,075.23, with a payout of RMB 1.42 per 10 shares[17]. - The total number of restricted shares at the end of the period was 264,574,537, with an increase of 61,875 shares during the period[16]. - The company terminated the implementation of the 2022 restricted stock incentive plan, with 18,273,500 shares rendered void[17].